

AMENDMENT TO THE CLAIMS

Claims. 1-25 (canceled)

Claim 26. (Previously Presented) A method for the treatment of a condition in a mammal, said method comprising administering to said mammal an effective amount of or a pharmaceutically acceptable salt thereof, wherein said condition is multiple sclerosis.

Claims 27-43 (Canceled)

Claim 44. (Currently Amended) The method of claim 26, wherein said administering is selected from a group consisting of administering respiratorally, intratracheally, nasopharyngeally, intravenously, intraperitoneally, nasopharyngeally, intravenously, intraperitoneally, subcutaneously, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intracerebrally, intranasally, infusion, orally, rectally, via IV drip, patch and implant.

Claim 45. (Previously Presented) The method of claim 26, wherein said effective amount is from about 0.1 mg to about 1 mg per kilogram body weight per day of said mammal.

Claim 46. (Previously Presented) The method of claim 26, wherein said tranilast or pharmaceutically acceptable salt is administered orally.

Claim 47. (Previously Presented) The method of claim 26, wherein said administration is daily, weekly, or monthly.

Claims 48-56. (Canceled)

Claim 57. (New) The method of claim 26, wherein said effective amount is from about 0.1 μ g to 2000 mg.

Claim 58. (New) The method of claim 26, wherein said administering is via a tablet, troche, pill, capsule, syrup, suspension, wafer or elixir.

Claim 59. (New) The method of claim 26, wherein said tranilast or a pharmaceutically acceptable salt thereof is present in a composition at least 1% by weight of said composition.

Claim 60. (New) The method of claim 26, wherein said tranilast or a pharmaceutically acceptable salt thereof is present in a composition at about 5% to about 80% by weight of said composition.